User login
Key clinical point: In this real-world analysis of patients with psoriatic arthritis (PsA), interleukin-12/23 inhibitor (IL-12/23i) demonstrated longer persistence and higher adherence than tumor necrosis factor inhibitors (TNFi) and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs).
Major finding: At 1 year, persistence was significantly longer among patients who initiated IL-12/23i vs. TNFi (269 vs. 215 days) or tsDMARD (269 vs. 213 days; both P less than .001). Adherence was significantly higher among patients who initiated IL-12/23i vs. TNFi (0.64 vs. 0.56; P = .004) or tsDMARDs (0.64 vs. 0.58; P = .027).
Study details: In this retrospective observational analysis, 7,205 patients with PsA who newly initiated a targeted immune modulator were matched (1:1) in IL-12/23i vs. TNFi (n=238), IL-12/23i vs. tsDMARD (n=238), and IL-12/23i vs. IL-17i (n=189) patient pairs.
Disclosures: This study was funded by Janssen Scientific Affairs, LLC. LA Walsh declared receiving grants and/or serving as a consultant for various pharmaceutical companies. Q Cai, I Lin, CD Pericone, and SD Chakravarty declared being current employees of Janssen Scientific Affairs, LLC and stockholders in Johnson & Johnson.
Source: Walsh JA et al. Adv Ther. 2021 Mar 23. doi: 10.1007/s12325-021-01687-w.
Key clinical point: In this real-world analysis of patients with psoriatic arthritis (PsA), interleukin-12/23 inhibitor (IL-12/23i) demonstrated longer persistence and higher adherence than tumor necrosis factor inhibitors (TNFi) and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs).
Major finding: At 1 year, persistence was significantly longer among patients who initiated IL-12/23i vs. TNFi (269 vs. 215 days) or tsDMARD (269 vs. 213 days; both P less than .001). Adherence was significantly higher among patients who initiated IL-12/23i vs. TNFi (0.64 vs. 0.56; P = .004) or tsDMARDs (0.64 vs. 0.58; P = .027).
Study details: In this retrospective observational analysis, 7,205 patients with PsA who newly initiated a targeted immune modulator were matched (1:1) in IL-12/23i vs. TNFi (n=238), IL-12/23i vs. tsDMARD (n=238), and IL-12/23i vs. IL-17i (n=189) patient pairs.
Disclosures: This study was funded by Janssen Scientific Affairs, LLC. LA Walsh declared receiving grants and/or serving as a consultant for various pharmaceutical companies. Q Cai, I Lin, CD Pericone, and SD Chakravarty declared being current employees of Janssen Scientific Affairs, LLC and stockholders in Johnson & Johnson.
Source: Walsh JA et al. Adv Ther. 2021 Mar 23. doi: 10.1007/s12325-021-01687-w.
Key clinical point: In this real-world analysis of patients with psoriatic arthritis (PsA), interleukin-12/23 inhibitor (IL-12/23i) demonstrated longer persistence and higher adherence than tumor necrosis factor inhibitors (TNFi) and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs).
Major finding: At 1 year, persistence was significantly longer among patients who initiated IL-12/23i vs. TNFi (269 vs. 215 days) or tsDMARD (269 vs. 213 days; both P less than .001). Adherence was significantly higher among patients who initiated IL-12/23i vs. TNFi (0.64 vs. 0.56; P = .004) or tsDMARDs (0.64 vs. 0.58; P = .027).
Study details: In this retrospective observational analysis, 7,205 patients with PsA who newly initiated a targeted immune modulator were matched (1:1) in IL-12/23i vs. TNFi (n=238), IL-12/23i vs. tsDMARD (n=238), and IL-12/23i vs. IL-17i (n=189) patient pairs.
Disclosures: This study was funded by Janssen Scientific Affairs, LLC. LA Walsh declared receiving grants and/or serving as a consultant for various pharmaceutical companies. Q Cai, I Lin, CD Pericone, and SD Chakravarty declared being current employees of Janssen Scientific Affairs, LLC and stockholders in Johnson & Johnson.
Source: Walsh JA et al. Adv Ther. 2021 Mar 23. doi: 10.1007/s12325-021-01687-w.